Oral manifestations of lichen planus in patients with hepatitis C virus and HIV/AIDS
Abstract number: 1733_723
Giovani E., Souza R., Cavasin J., Egashira S., Melo J., Armonia P., Andia-Merlin R.
Objective: The aim of this study was to investigate the prevalence of oral lichen planus (OLP) in patients with hepatitis C virus (HCV), and or in the patients with HIV/Aids.
Material and Method: All the patients were investigated on the presence of antibodies anti-HCV and anti-HIV. The parameters analysed included prevalence of the oral lichen planus, age, gender, race, and the counting of the lymphocytes T-CD4.
Results: A total of 165 patients have anti-HCV antibodies and or with co-infection for HIV/Aids, being 91 patients (55.2% male), and 74 patients (44.8% female). The medium age was 37 years for both sexes, and they were divided in 2 groups. Group I: 59 patients (35.8%) have anti-HCV antibodies and negative HIV antibodies, 32 were male (54.2%) and 27 (45.8%) were female, 5 patients (8.5%) exhibited OLP: 2 patients in the erosive pattern (1 male and 1 female), 1 in the mixed pattern (male) and 2 patients with the reticular pattern (1 male and 1 female). Group II: 106 patients (64.2%) have anti-HCV antibodies and positive HIV antibodies, 59 were male (55.7%), 47 were female (44.3%), 14 (13.2%) patients exhibited OLP: 5 patients with the erosive pattern (3 male and 2 female), 4 patients with the mixed form (2 male and 2 female), and 5 patients with the reticular pattern (2 male and 3 female), and all the patients make therapy only or combined of interferon and or ribavirina. As for the counting of the lymphocytes T-CD4, 33 patients (31.1%) with values below 200 cél/mm3 of blood, 55 patients (51.9%) they presented values among 200 to 499 cél/mm3 of blood, 18 patients (17%) with values above 500 cél/mm3.
Conclusion: The patients with counting of the lymphocytes low T-CD4 and that use ribavirina and the interferon exhibited more exuberant OLP in the several patterns. We still observed the presence of OLP in the erosive pattern in patients of the masculine sex.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|